Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Recommendation of “Buy” from Brokerages

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been assigned an average rating of “Buy” from the fifteen ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, twelve have given a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $100.25.

MIRM has been the subject of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Wednesday, October 8th. JPMorgan Chase & Co. boosted their target price on Mirum Pharmaceuticals from $53.00 to $77.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Evercore ISI increased their price target on shares of Mirum Pharmaceuticals from $89.00 to $94.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Cowen assumed coverage on Mirum Pharmaceuticals in a report on Wednesday, September 24th. They set a “buy” rating for the company. Finally, Morgan Stanley increased their price target on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $81.12 on Thursday. The firm has a market cap of $4.17 billion, a P/E ratio of -94.32 and a beta of 0.42. Mirum Pharmaceuticals has a twelve month low of $36.88 and a twelve month high of $82.58. The firm’s 50 day moving average price is $70.90 and its two-hundred day moving average price is $65.33. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. The firm had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company’s revenue was up 47.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.30) EPS. On average, analysts forecast that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently modified their holdings of MIRM. MCF Advisors LLC increased its position in Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares in the last quarter. Quantbot Technologies LP bought a new stake in Mirum Pharmaceuticals during the 3rd quarter worth approximately $33,000. Comerica Bank grew its holdings in Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares in the last quarter. Quarry LP bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth $41,000. Finally, CWM LLC increased its stake in Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after buying an additional 161 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.